The team boasts 25 years of global executive experience in leading Pharmaceutical, Medical Diagnostics & Devices companies. Sayre Therapeutics has been identified as a high potential healthcare company, a pedigree team with proven wins and a robust clinician network in the Oncology / Immunology space. The company is uniquely positioned with a first-mover advantage, which allows for it to quickly create a portfolio of differentiated global assets in emerging markets.
Sayre is backed by two leading venture capital firms (VCs).
Our geographic footprint covers India, South Asian and South-East Asian countries which are witnessing a high growth rate across the disease areas of interest. Sayre Therapeutics with its focused strategy, strong financial backing and established relationships with clinicians and regulatory know-how, will be nimble and to that end, will prove to be a committed partner to licensors for their global assets.
We will become Asia’s specialized healthcare company of choice, providing patients and clinicians access to high-quality novel medical solutions for life-threatening diseases.
Leading the way by providing access to innovative and affordable treatment options, to improve the quality of life.